KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE.

Yuko Mishima, Daigo Hashimoto, Michiko Ichii, Noriko Fukuhara, Toshiki Uchida, Koji Kato, Ai Omi, Yosuke Koroki, Kaname Shiga, Dai Maruyama

Ann Hematol 104(9) 4605-4610

PMID40940567
PMCIDPMC12552230
DOI10.1007/s00277-025-06569-7
发表日期2025-09-12
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

Ibrutinib is a first-in-class oral inhibitor of Bruton's tyrosine kinase, which was investigated for the first-line treatment of mantle cell lymphoma (MCL) in the randomized, double-blind, phase 3 SHINE study. In SHINE, ibrutinib plus bendamustine and rituximab (BR) demonstrated superior progression-free survival (PFS) versus placebo plus BR in patients aged ≥ 65 years with previously untreated stage II-IV MCL. In this secondary efficacy analysis of SHINE, we assessed the correlation between best response and PFS (n = 523; 70% male; median age 71.0 years). After a median follow-up of 94.5 months, patients achieving complete response (CR) had longer median PFS in the ibrutinib (97.8 months) and placebo (87.9 months) arms than those with partial response (PR; 27.6 and 16.7 months, respectively) or progressive/stable disease (2.9 and 3.4 months, respectively). In the multivariate logistic regression analysis, patients receiving ibrutinib plus BR were more likely to achieve CR than those receiving placebo plus BR (odds ratio 1.48; 95% confidence interval 1.00-2.22). In conclusion, prolonged long-term PFS was more likely in patients with MCL who achieved CR following treatment with either ibrutinib plus BR or placebo plus BR, while CR was more likely in patients who had received ibrutinib plus BR. TRIAL REGISTRATION: EU Clinical Trials Register (EudraCT) identifier 2012-004056-11 (registered 15 January 2013) WHO Universal Trial Number U1111-1137-0389.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 1

Fig. 1 Progression-free survival by best response. BR, bendamustine and rituximab; CR, complete response; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease

PFS_by_best_response

Progression-free survival

Fig. 1 · Panel PFS_by_best_response

quality_warning 待 EXE 对齐 预期 6 条 已提取 4 条

Panel PFS_by_best_response 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 6 条,实际恢复 4 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果